EVAX
Evaxion A/S
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Evaxion A/S
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
No changes.
No changes.
No peers for Evaxion A/S yet.
No peers for Evaxion A/S yet.
Annual filing, covered
20-F parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Evaxion Biotech A/S, an artificial intelligence (AI)-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. Its proprietary AI platforms include PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. The company develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase 1/2a trial for indications, such as metastatic and unresectable melanoma; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in Phase 2b trial for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are in pre-clinical stage for the treatment of infectious diseases. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate; and a clinical trial collaboration and supply agreement with MSD International GmbH and MSD International Business GmbH. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Evaxion Biotech A/S, an artificial intelligence (AI)-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. Its proprietary AI platforms include PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. The company develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase 1/2a trial for indications, such as metastatic and unresectable melanoma; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in Phase 2b trial for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are in pre-clinical stage for the treatment of infectious diseases. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate; and a clinical trial collaboration and supply agreement with MSD International GmbH and MSD International Business GmbH. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
—
Evaxion A/S
2.93
−0.15 · −4.87%
post 2.93 0.00%
Linked news
Expected move
No implied move.
+0.63%
shares held · 10 largest managers
| Manager | Value | % base | |
|---|---|---|---|
| Merck | $3.8M | 76.29% | new |
| Ikarian Capital | $231,564 | 4.69% | 0.00% |
| Rathbone Brothers | $141,741 | 2.87% | 0.00% |
| Citadel | $113,410 | 2.30% | +105.84% |
| Renaissance Technologies | $104,780 | 2.12% | −13.83% |
| Manager | Value | % base | |
|---|---|---|---|
| Merck | $3.8M | 76.29% | new |
| Ikarian Capital | $231,564 | 4.69% | 0.00% |
| Rathbone Brothers | $141,741 | 2.87% | 0.00% |
| Citadel | $113,410 | 2.30% | +105.84% |
| Renaissance Technologies | $104,780 | 2.12% | −13.83% |